Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors

Next Previous
Trial Profile

A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TAC-001 (Primary)
  • Indications Cholangiocarcinoma; Malignant melanoma; Solid tumours
  • Focus First in man; Therapeutic Use
  • Acronyms INCLINE-101
  • Sponsors Tallac Therapeutics

Most Recent Events

  • 30 Apr 2025 Results (As of September 11, 2024, n=72) assessing the safety, tolerability, pharmacokinetics (PK), immunogenicity, tumor biopsy pharmacodynamic (PD) effects, and preliminary efficacy of TAC-001 across multiple solid tumors presented at the 116th Annual Meeting of the American Association for Cancer Research
  • 16 Aug 2024 Status changed from recruiting to active, no longer recruiting.
  • 03 Nov 2023 Results presented in the Tallac Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top